Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia in Situ, and Germ Cell Tumors of the Testis-Reference-Cited by-同舟云学术

Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia in Situ, and Germ Cell Tumors of the Testis

Published:2021-12-01 Issue: Volume: Page:
ISSN:0002-9173
Container-title:American Journal of Clinical Pathology
language:en
Short-container-title:

Author:

Ricci Costantino¹²^ORCID,Franceschini Tania³,Giunchi Francesca³,Grillini Marco³^ORCID,Ambrosi Francesca¹,Massari Francesco⁴,Mollica Veronica⁴^ORCID,Colecchia Maurizio⁵,Fiorentino Michelangelo¹²³

Affiliation:

1. Department of Pathology, Maggiore Hospital, AUSL-Bologna, Bologna, Italy

2. Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy

3. Department of Pathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

4. Department of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

5. Department of Pathology, IRCCS San Raffaele Scientific Institute, Milano, Italy

Abstract

Abstract Objectives Preferentially expressed antigen in melanoma (PRAME) has a key role in regulating pluripotency of primordial germ cells and in the development of germ cell tumors of the testis (GCTT). However, its immunohistochemical expression in normal testes and its neoplastic counterpart remain largely unknown. Methods We retrospectively investigated the expression of PRAME in 26 cases of GCTT, 21 cases of germ cell neoplasia in situ (GCNIS), and 17 cases of uninvolved background testes. Results We found that PRAME was expressed more strongly by seminomatous rather than nonseminomatous GCTT (P = .000) and by pure seminoma rather than the seminoma component of seminomatous/nonseminomatous GCTT (P = .025). In addition, GCNIS and uninvolved background testes displayed high levels of PRAME expression. Conclusions PRAME is an additional marker for the differential diagnosis of GCTT and could play a key role in the transition from seminomatous to nonseminomatous GCTT.

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Link

https://academic.oup.com/ajcp/advance-article-pdf/doi/10.1093/ajcp/aqab200/41429295/aqab200.pdf

Reference26 articles.

1. The PRAME family of cancer testis antigens is essential for germline development and gametogenesis;Kern;Biol Reprod.,2021

2. The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas;Nettersheim;Br J Cancer.,2016

3. SOX2 is essential for in vivo reprogramming of seminoma-like TCam-2 cells to an embryonal carcinoma-like fate;Nettersheim;Oncotarget.,2016

4. BMP inhibition in seminomas initiates acquisition of pluripotency via NODAL signaling resulting in reprogramming to an embryonal carcinoma;Nettersheim;PLoS Genet.,2015

5. PRAME as diagnostic marker and as regulator for cell fate decisions in germ cell cancers;Neuhaus;Br J Cancer.,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression of Preferentially Expressed Antigen in Melanoma, a Cancer/Testis Antigen, in Carcinoma In Situ of the Urinary Tract;Diagnostics;2023-12-10

2. Exploring the Complex and Multifaceted Interplay between Melanoma Cells and the Tumor Microenvironment;International Journal of Molecular Sciences;2023-09-21

3. Preferentially Expressed Antigen in Melanoma Is a Multifaceted Cancer Testis Antigen with Diverse Roles as a Biomarker and Therapeutic Target;International Journal of Translational Medicine;2023-08-29

4. TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis;Pathology - Research and Practice;2023-07

5. FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal‐type;Histopathology;2023-06-14